(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]-N-[4-[1-hydroxy-2-(4-methylpiperazin-1-yl)-2-oxoethyl]phenyl]pentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]-N-[4-[1-hydroxy-2-(4-methylpiperazin-1-yl)-2-oxoethyl]phenyl]pentanamide
• 化学式: C₄₂H₆₅N₉O₁₃
• 分子量: 904.0
• InChiKey: GYKSZGTUFJROJB-DQHSECSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  64
• 可旋转键数：
  30
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  290
• 氢给体数：
  7
• 氢受体数：
  14

文献信息

• [EN] ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF<br/>[FR] CONJUGUÉS ANTICORPS ANTI-CD22-MÉDICAMENT ET LEURS MÉTHODES D'UTILISATION
  申请人：BIOALLIANCE CV

  公开号：WO2015196089A1

  公开（公告）日：2015-12-23

  The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.

  本公开提供包含亲水性自解离连接剂的抗CD22抗体药物偶联物。本公开还提供用于治疗癌症的组合物和方法。
• HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF
  申请人：BioAlliance C.V.

  公开号：US20140193437A1

  公开（公告）日：2014-07-10

  The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
• ANTI-FOLATE RECEPTOR ALPHA (FRA) ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
  申请人：BIOALLIANCE C.V.

  公开号：US20160015827A1

  公开（公告）日：2016-01-21

  The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
• HER2 ANTIBODY-DRUG CONJUGATES
  申请人：AbGenomics International Inc.

  公开号：US20160051695A1

  公开（公告）日：2016-02-25

  The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleaved under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker. In some aspects of the present disclosure, the targeting moiety is an anti-HER2 antibody. The present disclosure further provides compositions and methods for treating cancers.
• ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
  申请人：BioAlliance C.V.

  公开号：US20160015831A1

  公开（公告）日：2016-01-21

  The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.